INVITED EDITORIAL
 
TOPICS
REFERENCES (10)
1.
Lonardo A, Zheng MH, Eslam M. MASLD vs. MAFLD. A narrative review. Explor Dig Dis 2025; 4: 100586.
 
2.
Lonardo A, Ballestri S, Baffy G, Weiskirchen R. Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease. Metab Target Organ Damage 2024; 4: 41.
 
3.
Lonardo A. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review. Metab Target Organ Damage 2024; 4: 16.
 
4.
Jamalinia M, Lonardo A. Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge. Metab Target Organ Damage 2024; 4: 23.
 
5.
Lonardo A, Stefan N, Mantovani A. Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. Trends Endocrinol Metab 2025; 36: 610-3.
 
6.
Younossi ZM, Paik JM, Lazarus JV, et al. Projected global clinical, humanistic, and economic impact of metabolic dysfunction-associated steatohepatitis (MASH): the cost of inaction based on data from nine countries. Clin Gastroenterol Hepatol 2026; 24: 1016-34.
 
7.
Yang YL, Li Y. Daily sedentary behavior exceeding 5 hours is independently associated with MAFLD: a cross-sectional study from NHANES 2017-2020. Arch Med Sci 2026, In press.
 
8.
Parker KM, Tucker LA, Bailey BW, Davidson LE. Relationship between sitting time and insulin resistance in 6931 U.S. adults: the mediating role of abdominal adiposity. J Diabetes Res 2023; 2023: 5015572.
 
9.
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
 
10.
Lonardo A, Jamalinia M, Weiskirchen R. Biological determinants and outcomes of sex discrepancies in MASLD. Metab Target Organ Damage 2026; 6: 4.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top